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Background: Pregnancy could be associated with renal physiologic changes; hence the use of atazanvair/ritonavir 
(ATV/r) in pregnant women with human immunodeficiency virus (HIV) could be of safety concern due to its 
nehprotoxic potential.  
Objective: The present study was aimed at assessing the renal profile of atazanavir/ritonavir (ATV/r) in pregnant 
albino rats. 
Methods: Thirty six pregnant albino rats were randomized into six groups (A-E) of n=6. Rats in groups A and B were 
treated with water and normal saline as placebo and solvent control respectively. Rats in groups C-F were orally 
treated daily with 4.28/1.43, 8.57/2.86, 17.1/5.7 and 34/11.4 mg/kg of ATV/r for 16 days. Rats were weighed, 
sacrificed and blood was collected and serum extracted. The serum was evaluated for creatinine (Cr), urea (U), uric 
acid (UA), total protein (TP), albumin (Ab), potassium (K+), sodium (Na+), chloride ( Cl-) and bicarbonate (HCO3 -). 
Kidneys were harvested, weighed and evaluated for superoxide dismutase (SOD), catalase (CAT) glutathione (GSH), 
glutathione peroxidase (GPX) and malondialdehyde (MDA) levels. Kidneys were also evaluated for histological 
damage. 
Results: ATV/r-treated groups did not show significant (p> 0.05) changes in the body weight, kidney weight and 
serum electrolytes, however; serum levels of Cr, U, UA were significantly (p< 0.05) increased whereas Ab and TP were 
significantly (p< 0.05) decreased in a dose-dependent manner. Kidney SOD, CAT, GSH and GPX levels were 
significantly (p< 0.05) decreased whereas MDA levels were significantly (p< 0.05) increased in a dose dependent 
manner in ATV/r-treated rats. Varying degrees of histological damage were observed in the kidneys of ATV/r treated 
rats. 
Conclusion: This study observed dose-dependent nephrotoxic effects in ATV/r-treated pregnant albino rats. 
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1. Introduction 
The introduction of highly active antiretroviral therapy 
(HAART) has led to a dramatic decline in mortality and 
morbidity associated with HIV  infection, however, a 
variety of adverse renal effects due to antiretroviral 
drugs have been recognized (Izzedine et al, 2009). Since 
the kidney plays a major role in the metabolism and 
excretion of antiretroviral drugs, it is vulnerable to 
various types of renal injuries associated with 
antiretroviral drugs (Kalyesubula and Perazella 
2011). Antiretroviral associated kidney injuries occur 
via multiple mechanisms, including direct tubular 
toxicity, allergic reactions, and precipitation of insoluble 
drug crystals within renal tubular lumens (Perazella, 
2010).  
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The use of antiretroviral drugs in pregnancy, has 
decreased vertical transmission rate to less than 2%, 
delayed disease progression and reduced the risk of HIV 
transmission to HIV-serodiscordant partners. Although 
these results are notable, maternal toxicities associated 
with the use of specific antiretroviral drugs during 
pregnancy remain a serious concern (Burdge et al, 
2003; van Schalkwyk et al, 2008). Renal toxicity could 
be a serious clinical challenge in the provision of 
antiretroviral therapy during pregnancy due to the fact 
that in some cases, pregnancy could be associated with 
acute kidney injury or acute renal failure (Lang and 
Jones, 1964).  Pregnancy associated acute kidney injury 
is difficult to diagnose, hard to predict and often 
diagnosed after significant damage to the kidney (Van 
Hook, 2014). It is often characterized by deterioration 
in renal function, resulting in the accumulation of 
nitrogenous waste products, electrolyte homeostatic 
aberrations and extracellular volume abnormalities 
(Kellum et al, 2012). Also, evidence showed that 
pregnancy may affect the incidence of treatment related 
adverse effects including adverse renal effects (Clark, 
2005). 
ATV/r combination belongs to the protease inhibitor 
family and could be used for the management of HIV in 
pregnancy. The PIs have shown significant decreases in 
maternal viral load in HIV positive women when 
compared to other regimens and could decrease the 
need for cesarean delivery and intrapartum zidovudine 
and minimize vertical transmission to infants (Duryea 
et al, 2015), The use of PI-containing HAART especially 
ATV/r could be associated with renal toxicity (Chan-
Tack et al, 2007; Hamada et al, 2012). ATV/r has the 
potential to yield its crystal in urine and renal 
interstitial tissues, leading to crystalluria, urolithiasis, 
acute kidney injury (AKI) or chronic kidney disease 
(CKD) (Hara et al, 2015).Therefore use in pregnancy 
may present an important safety concern because 
pregnancy is characterized by acute kidney injury, renal 
physiological alterations, including changes in kidney 
size as well as glomerular and tubular function (Davison 
and Dunlop 1980; Odutayo et al, 2012).  Therefore, this 
study assessed the renal profile of ATV/r in a pregnant 
rat model. 
2. Methods 
2.1 Drugs  
The sample of ATV/r used for this study was produced 
by Myland laboratories limited, India. All other 
chemicals used for this study are of analytical grade. 
This study used 4.28/1.43, 8.57/2.86, 17/5.72, and 
34/1 1.4 mg/kg/day of ATV/r which represent clinical 
dose, 2, 4 and 8 times the clinical dose (Guiard-Schmid 
et al, 2005). ATV/r used for the study was suspended in 
normal saline (Youssef et al, 2015). Higher doses of 
ATV/r were used because antiretroviral drugs are used 
for life and may accumulate. Also, laboratory animals’ 
metabolize and excrete drugs faster than humans 
(Lüllmann et al, 1975).  
2.2  Animals 
Pregnant albino rats of average weight 180 ± 5g used 
for this study were obtained from the animal house of 
the Department of Pharmacology and Toxicology 
Madonna University, Elele, Rivers State. The rats were 
housed in individual cages and exposed to a 12-h light–
dark cycle, with the light cycle coinciding with daylight 
hours. The rats were allowed free access to food and 
water ad libitum. 
The reproductive status and estrous period of the rats 
were determined by obtaining their virginal smears. 
After two complete regular cycles, timed mating of 
female rats was done on the night of the pro-estrous (N) 
phase of the cycle. In the morning following mating, 
vaginal smears were taken again. The presence of 
spermatozoa and squamous cells in the smear 
confirmed mating and fertilization of ovules. The sperm 
– positive morning was thus designated day 0 of 
pregnancy. 
This study used thirty six (36) pregnant albino rats 
which were divided into six groups A –F of six rats each. 
Group A (Placebo control) and Group B (Solvent 
control) were treated orally with water and normal 
saline respectively. Groups C – F were treated orally 
with 4.28/1.4, 8.57/2.86, 17/5.72, and 34/1 1.4 mg/kg 
of ATV/r for 16 days respectively. All rats were treated 
from the 1st -16th day of gestation. 
2.3 Collection of samples 
The rats were sacrificed with the aid of inhalational 
diethyl ether at the end of drug treatment and blood 
samples were collected via cardiac puncture in sterile 
non-heparinized containers. Blood samples were 
centrifuged at 1500rpm for 20 minutes and serum was 
extracted and analyzed for renal function parameters.   
Kidneys were collected via dissection and washed in an 
ice cold 1.15% KCl solution. Kidneys were homogenized 
with 0.1M phosphate buffer (pH 7.2) and centrifuged at 
1500rpm for 20 minutes. Supernatant was decanted 
and evaluated for kidney levels of oxidative stress 
indices.  
2.4 Evaluation of renal function parameters  
Creatinine was evaluated using Jaffe’s deproteinisation 
method 1886 while urea was evaluated using diacetyl 
monoxime method (Okonkwo et al, 2013). Uric acid was 
evaluated as reported by Sanders et al, 1980. Albumin 
was evaluated using endpoint method as reported by 
Tietz et al, (1994) while total protein content was 
evaluated using Biuret method as described by 
Plummer, (1971).  
Serum potassium and sodium were determined using 
flame photometric methods, while chloride levels were 
determined using titrimetric method. Bicarbonate was 
evaluated using standard laboratory test kits. 
2.5 Oxidative stress marker assay 
Superoxide dismutase activity was evaluated as 
reported by Sun and Zigman 1978 while catalase was 
evaluated as reported by Aebi 1984. Reduced 
glutathione was analyzed according to Sedlak and 
Lindsay 1968 while glutathione peroxidase was 
evaluated as described by Rotruck et al, 1973.  
Malondialdehyde was evaluated as reported by Buege 
and Aust, 1978.  
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2.6 Histopathological examination 
Collected kidney was fixed in 10% formalin in labeled 
bottles. Kidney tissues were processed routinely and 
embedded in paraffin wax. Sections of 5 μ thickness 
were cut, stained with haematoxylin and eosin and 
examined under a light microscope. 
2.7 Statistical analysis  
Results were expressed as mean ± SD. The data were 
subjected to one way analysis of variance (ANOVA) test 
and Dunnett’s multiple range post-hoc test. Results 
were considered to be significant at p<0.05.  
3. Results  
Treatment with ATV/r did not produce significant 
(p>0.05) effects on the body, absolute and relative 
kidney weights when compared to placebo control 
(Table 1).  
In Table 2, the present study observed significant 
(p<0.05) and dose-dependent increases in serum 
creatinine (Cr), urea (U), and uric acid (UA). On the 
other hand, significant (p<0.05) and dose-dependent 
decreases were observed in total protein (TP) and 
albumin (Ab) levels when compared to the levels of 
these parameters in the placebo control rat. Cr levels 
were increased by 41.8%, 87.3%, 154.5%, and 276.4%, 
whereas UA levels were increased by 52.6%, 97.3%, 
170.6%, and 321.0%. The observed increases in U 
represent 42.1%, 94.7%, 161.4% and 222.6% at 
4.28/1.43mg/kg, 8.57/2.86mg/kg, 17/5.72mg/kg, and 
34/1 1.4 mg/kg of ATV/r, respectively. 
Furthermore, treatment with ATV/r did not produce 
significant (p>0.05) effects on serum K+, Na+, Cl– and 
HCO3- when compared to control (Table 3). However, 
kidney levels of GSH, CAT, SOD and GPX were decreased 
while MDA levels were increased significantly (p<0.05) 
and in a dose dependent manner when compared to 
control. GSH levels were decreased by 14.6 %,, 35.0%, 
55.7%, and 75.0% while GPX levels were decreased by 
13.3 %, 34.0%, 57.3%, and 74.5% at  4.28/1.43mg/kg, 
8.57/2.86mg/kg, 17/5.72mg/kg, and 34/1 1.4 mg/kg of 
ATV/r respectively. Also, SOD levels were decreased by 
13.2%, 36.1%, 51.1%, and 70.6%, whereas CAT levels 
were  decreased by 12.7 %, 39.9%, 63.8%, and 99.9%, 
at 4.28/1.43mg/kg, 8.57/2.86mg/kg, 17/5.72mg/kg, 
and 34/1 1.4 mg/kg of ATV/r respectively (Table 4).  
 
  Table1: Effects of atazanavir-ritonavir on body and kidney weights of pregnant albino rats  
Groups Body weight (g) Absolute kidney weight(g) Relative kidney weight (%) 
A  (placebo) 250±12.4 0.97±0.08 0.39 ±0.06 
B  (solvent) 245±12.9 0.90±0.07 0.37 ±0.09 
C 230±10.5 0.93±0.03 0.40 ± 0.01 
D 240±11.7 0.99±0.04 0.41 ± 0.08 
E 245±10.8 1.03±0.06 0.42 ± 0.03 
F 252±13.1 1.00±0.08 0.40 ± 0.08 
   ATV=Atazanavir-ritonavir. Data are expressed as mean± SD.  n=6 
 
Table 2: Effects of atazanavir-ritonavir on serum renal function parameters of pregnant albino rats 
Groups 
Creatinine 
(mg/dL) 
Urea 
(mg/dL) 
Uric acid 
(mg/dL) 
Albumin 
(mg/dL) 
T. Protein 
(mg/dL) 
  A(placebo) 1.10±0.03a 33.3±3.14a 1.14±0.05a 5.98±0.15a 9.79±0.27a 
  B (solvent) 1.21± 0.01a 31.0±2.00a 1.10±0.03a 5.70±0.41a 9.65±0.51a 
  C 1.56±0.05b 50.8±3.11b 1.62±0.04b 4.85±0.25a 8.66±0.29a 
  D 2.06±0.04c 65.7±1.76c 2.22±0.09c 3.53±0.04b 5.31±0.10b 
  E 2.80±0.06d 90.1±6.85d 2.98±0.08d 2.25±0.08c 3.14±0.03c 
  F 4.14±0.08e 140.2±10.1e 3.70±0.15e 1.00±0.69d 1.04±0.01d 
ATV=Atazanavir-ritonavir.  n=6. Data are expressed as mean± SD.  Values with different superscript on the same column differ 
significant at (P<0.05) ANOVA and Dunnett’s multiple range post-hoc test. 
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Table 3: Effect of atazanavir-ritonavir on serum electrolytes of pregnant albino rats 
Groups K + (mEq/L) Na + (mEq/L) Cl - (mEq/L) HC03 - (mEq/L) 
A(placebo) 4.33± 0.06 137.2± 6.25 97.3 ± 5.00 29.9± 3.22 
B (solvent) 4.45 ± 0.07 140.3 ± 7.11 90.1 ± 7.21 30.6± 4.51 
C 4.24 ± 0.01 138.3 ± 9.14 96.6 ± 4.01 32.1± 2.01 
D 4.22 ± 0.03 130.0± 5.24 96.1 ± 4.08 30.9± 2.34 
E 4.20 ± 0.05 133.2 ± 4.75 94.7 ± 5.11 31.6± 2.72 
F 4.15 ± 0.03 128.6± 6.20 89.3±  6.73 33.0± 2.54 
 ATV=Atazanavir-ritonavir. Data are expressed as mean± SD.  n=6 
 
Table 4: Effect of atazanavir-ritonavir on kidney oxidative stress indices of pregnant albino rats 
Groups 
MDA 
(nmol/mg protein) 
SOD 
(U/mg protein) 
CAT 
(U/mg protein) 
GSH 
(µg/mg protein) 
GPX 
(µg/mg protein) 
A(placebo) 0.55±0.03a 21.9±1.06a 25.3±1.22a 15.8±0.24a 18.0±0.97a 
B(solvent) 0.53± 0.06a 20.1±2.00a 24.9±2.11a 15.6±0.17a 18.5±0.65a 
C 0.62±0.02a 19.0±1.44a 22.1±0.77a 13.5±0.62a 15.6±0.41a 
D 0.78±0.02b 14.0±1.51b 15.2±0.12b 10.25±0.39b 11.8±0.54b 
E 1.00±0.02c 10.7±1.30c 7 .17±1.41c 7.00±0.66c 7.69±0.63c 
F 1.35±0.57d 6.43±1.67d 4.01±0.19d 3.80±0.48d 4.05±0.47d 
ATV=Atazanavir-ritonavir. n=6.  Data are expressed as mean± SD. Values with different superscript on the same column differ 
significant at (P<0.05) ANOVA and Dunnett’s multiple range post-hoc test 
 
The kidney of the control rat showed normal histology 
also, the kidney of pregnant rat treated with4.28/1.43 
mg/kg showed normal histology. However, the kidney 
of rat treated with 8.57/2.86 mg/kg of ATV/r showed 
tubular necrosis and sloughing of epithelial lining, 
whereas the kidney of rat treated with 17.1/5.74 mg/kg 
of ATV/r showed tubular necrosis and glomerular 
collapse. The kidney of rat that received 32.4/11.4 
mg/kg of ATV/r showed tubular necrosis, enlarged 
tubular epithelial cells and eosinophilic cytoplasm 
(Figure 1:A-E). 
4.0 Discussion 
Renal toxicity is an important concern in the provision 
of antiretroviral therapy in pregnancy. Renal injury 
associated with highly active antiretroviral therapy 
(HAART) include electrolyte imbalance to more serious 
incidents with acute renal failure (Atta et al, 2008).Also, 
pregnancy could be associated with acute kidney injury 
(Grünfeld and Pertuiset, 1997; Krane et al, 1998) which 
might be aggravated with the use of antiretroviral 
drugs. The present study assessed the renal profile of 
ATV/r in pregnant albino rats. The organ to body 
weight ratio gives a proportional size of the organ to 
body weight. It has been suggested that the use of 
organ/body weight ratio may be valuable in evaluating 
the relationship between certain experimental 
situations and the biological response of a test organism 
(Wilber et al, 1965). In this study, treatment with ATV/r 
did not produce significant effects on the body, absolute 
and relative kidney weights of pregnant rats.  
Creatinine is synthesized primarily in the liver from the 
methylation of glycocyamine by S-adenosyl methionine 
and is removed from the blood chiefly by the kidneys, 
via glomerular filtration and proximal tubular secretion 
(Gross et al, 2005; Allen et al, 2012). Uric acid is the end 
product of purine metabolism in humans which is 
filtered out of the blood by the kidney (Young et al, 
1987). Urea is major nitrogenous end product of protein 
and amino acid catabolism, produced by liver and is 
filtered out of blood by kidney glomeruli (Corbett, 
2008). Serum levels of creatinine, urea and uric acid are 
used as clinical end points to assess renal function. The 
current study observed increases in the serum levels of 
creatinine, urea and uric acid in a dose-dependent 
manner in ATV/r-treated pregnant rats.  The observed 
low clearance of creatinine, urea and uric acid indicates 
impaired ability of the kidneys to filter these waste 
products from the blood and excrete them in the urine. 
Hence, the elevated blood levels of creatinine, urea and 
uric acid are diagnostic of impaired renal function 
(Pagana et al, 1998). Quantification of serum protein is 
now a central part of screening and monitoring of 
kidney disease. Measurement of albumin level is one of 
the most prognostically significant biomarkers of 
kidney disease outcome and even cardiovascular 
disease and death (van der Velde et al, 2011).  
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A: Kidney of control pregnant rat showing normal 
histology (H&E stain, x400) 
B: Kidney of pregnant rat treated with 4.28/1.43 mg/kg 
showing normal histology (H&E stain, x400) 
  
C: Kidney of rat treated with 8.57/2.86 mg/kg of ATV/r 
showing sloughing of tubular epithelial lining and 
tubular necrosis (H&E stain, x400) 
D: Kidney of rat treated with 17.1/5.74 mg/kg of ATV/r 
showing tubular necrosis and glomerular collapse (H&E 
stain, x400) 
 
E: Kidney of rat treated with 32.4/11.4 mg/kg of ATV/r showing tubular necrosis, 
enlarged epithelial cells and eosinophilic cytoplasm (H&E stain, x400) 
Figure 1: Kidney photomicrographs showing kidney histology of treated and control rats 
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In the current study, assessment of serum albumin and 
total protein levels in ATV/r-treated pregnant rats 
showed dose-dependent decreases. This observation 
could be attributed to increase in the renal excretion of 
TP and Ab because renal pathology characterized by 
persistent urinary protein and albumin is a burdensome 
complication associated with long-term ATV/r use 
(Rockwood et al, 2011). 
K+, Na+, Cl- and HCO3- which are serum electrolytes 
found in the body’s cells and intracellular fluid perform 
essential regulatory functions. K+ along with glycogen 
plays a key role in transporting glucose into the muscle 
cells (Armstrong et al, 1985). Na+ and K+ are the co-
factor for the K+/Na+ ATPase activity (Ambwani et al, 
1999). Also, K+ interacts with Na+ and Cl- to control fluid 
and electrolyte balance and assists in the conduction of 
nerve impulse (Brouns, 1992). Considering the 
importance of electrolytes in body physiology, 
evaluation of K+, Na+, Cl- and HCO3- is often done for 
both diagnosis and management of renal, endocrine, 
acid-base, water balance and many other conditions 
(Gowda et al, 2010). In the present study, serum levels 
of K+, Na+, Cl-   and HCO3- were not significantly altered 
in ATV/r- treated pregnant rats.  
Malondialdehyde (MDA) is a highly reactive dialdehyde 
formed from the reaction of lipid hydroperoxide 
(LOOH) with alkoxyl radical (LO•). It is used as an index 
for lipid peroxidation and is associated with free radical 
production (Vancini et al, 2005). This study observed 
dose-dependent increases in the kidney levels of MDA 
in ATV/r-treated rats which indicate lipid peroxidation. 
SOD, CAT, GSH and GPX are integral components of 
antioxidant defence against oxidative radicals 
(Leeuwenburgh and Heinecke, 2001). SOD catalyzes the 
dismutation of superoxide to hydrogen peroxide, CAT 
catalyzes the decomposition of hydrogen peroxide to 
water and oxygen while reduced glutathione (GSH) 
chemically detoxifies hydrogen peroxide and forms 
oxidized glutathione (GSSG) (Khan et al, 2010) . Studies 
have shown that decreases in the levels of these 
antioxidants are pointers to free radical production and 
oxidative stress (Ansari, 2010; Omotayo et al, 2010). In 
the current study, dose-dependent decreases in the 
kidney levels of SOD, CAT, GSH and GPX were obtained 
in ATV/r-treated pregnant rats.   
The observed depletion in antioxidant levels could be 
attributed to ATV/r- induced oxidative stress through 
the generation of oxidative radicals in the kidneys of 
pregnant rats. Furthermore; the kidneys of the rats 
treated with the clinical dose of ATV/r showed normal 
kidney histology, however, histopathological alterations 
characterized by tubular necrosis were observed in the 
kidneys of rats treated with higher doses of ATV/r. In 
the present study, observed histopathological changes 
correlate with alterations in serum biochemical 
parameters and kidney oxidative stress indices.  The 
mechanism of ATV/r-induced nephrotoxicity is yet 
unknown, however, a number of mechanisms involved 
in antiviral-induced kidney injuries have been 
proposed. These include the overexpression or 
competitive inhibition of transport pumps which could 
lead to tubular cell toxicity (Cihlar et al, 1999; Ho et al, 
2000), activation of the mitogen-activated protein 
kinase pathway which can stimulate programmed cell 
death (Cihlar et al, 2002) and oxidative stress via 
damage mitochondria stimulating reactive oxygen 
species production which can disrupt fatty-acid 
oxidation and energy production (Cihlar et al, 2002; 
Saumoy et al, 2004). 
5.0 Conclusion  
This study was able to show that treatment with ATV/r 
produced dose-dependent nephrotoxic effects in 
pregnant albino rats. 
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